Introduction: This study aimed to assess treatment satisfaction and self-reported health
INTRODUCTION
A goal of diabetes treatment is to prevent diabetes complications and maintain as good quality of life (QOL) as those without diabetes, beginning from the fundamental step to achieve and maintain good glycemic control [1] . Although diligent life-long selfmanagement is required due to the progressive nature of diabetes [2, 3] , better glycemic control is associated with treatment satisfaction [4] and with better physical and psychological health [5] . Therefore, assessing treatment satisfaction and one's perception, i.e., health status and QOL, using patient-reported outcome (PRO) measures as important outcomes and also as factors influencing disease and treatment outcomes is an important part of diabetes management [6] . Basal-supported oral therapy (BOT) in which long-acting insulin injection is added to ongoing treatment with oral antidiabetic drugs (OADs) has been widely adopted for patients with type 2 diabetes mellitus (T2DM) whose blood glucose control using OADs is insufficient [7] . The simple and less frequent administration is expected to lower a barrier to initiation derived from anticipated or actual physical and psychological burden of insulin treatment, and make the management easier, which can consequently encourage healthcare providers to initiate insulin treatment at early treatment stage. Insulin glargine, one of the long-acting insulin analogs most commonly used in BOT, can supplement endogenous basal insulin effectively to reduce glycemic levels for approximately 24 h by once-daily injection with smaller risk of hypoglycemia [8] [9] [10] [11] .
In Japan, Add-on Lantus suggesting physiological efficacy and safety [12] . Although explored in other countries [13, 14] , glargine BOT's influence on treatment satisfaction and health status lacks data in Japanese patients, warranting the investigation specifically in a Japanese population. Anxiety and fear of insulin are known to hinder the introduction of insulin therapy [15] .
Investigating the influence of glargine BOT on treatment satisfaction and health status may give patients and their medical practitioners an incentive to introduce insulin without undue delay. In the present analysis, using a subset of data from the ALOHA2, we explored treatment satisfaction and self-reported health status in patients starting insulin glargine BOT.
METHODS

Study Design and Patients
The ALOHA2 study, a sequel of the ALOHA study [16] [17] [18] [19] , was conducted between 2012
and 2013 in 619 hospitals and clinics across Japan [12] . 
PRO Instruments
Patients' satisfaction and self-reported health status were measured using validated Japanese versions of three questionnaires: Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and change version (DTSQc) [21] and EuroQol 5 Dimension (EQ-5D) in the original 3-level format [22] . DTSQs and EQ-5D were administered at baseline, week 10 and week 24 or the last visit (final evaluation point)
and DTSQc at the final evaluation point. DTSQ simply and comprehensively assesses satisfaction specifically with diabetes treatment [23] . DTSQs captures the current status and DTSQc the change in treatment satisfaction [23, 24] . The instruments contain 8 questions: (1) satisfaction with current treatment, (2) perceived frequency of hyperglycemia, (3) perceived frequency of hypoglycemia, (4) convenience of the treatment, (5) flexibility of the treatment, (6) understanding of diabetes mellitus, (7) willingness to recommend the treatment to others, and (8) EQ-5D is a universally used tool to describe respondent's perceived health status [25] . The instrument includes the descriptive system and the visual analogue scale (EQ-VAS). The descriptive system consists of 5 dimensions: mobility, self-care, pain/discomfort, usual activities, and anxiety/depression, with three response levels: no problem, some problems, and extreme problems. The index score derived from the conversion of the total responses ranges from -0.11 to 1.00 in the Japanese population with the score of 1 denoting ''full health'' and 0 ''death'' [22] . EQ-VAS records respondent's general health ranging from 0 (worst imaginable health state) to 100 (best possible health state).
Statistical Analysis
Of the efficacy analysis set insulin-naïve 
Compliance with Ethics Guidelines
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RESULTS
Patient Characteristics
Of the 1251 patients included in this analysis ( Table 1 . The disease seemed to have progressed less in the target-achieved than in the targetnot-achieved group prior to baseline (i.e., a shorter duration of diabetes, fewer concomitant OAD, and lower percentage of patients with diabetic nephropathy (P\0.05 for all).
Mean HbA1c level significantly decreased in both groups at the final evaluation point from baseline (paired t test, P\0.0001) with significantly greater reduction in the targetachieved group (P\0.0001) (Fig. 2) . From baseline, both groups illustrated a similar trend of reduction (more than 1%) to week 12 and slight reduction (about 0.5%) in the targetachieved group and sideway shift with slight increase (less than 0.1%) in the target-notachieved group onwards to the final evaluation point.
Although data from patients who answered the questionnaire were analyzed, data from those who did not answer did not show significantly poorer glycemic control or higher incidence of treatment-related adverse events in this particular group of patients (P[0.05) (data not shown).
DTSQ
The mean DTSQs treatment satisfaction scale score significantly improved from baseline to the final evaluation point in overall patients (baseline vs final evaluation point: 21.8 vs 25.6, P\0.0001) and also in the target-achieved and target-not-achieved group (P\0.0001 for both) (Fig. 3a) . The mean change from baseline to the final evaluation point was significantly greater in the target-achieved group (mean ± standard deviation: 5.3 ± 8.0 and 3.2 ± 7.6, P = 0.001). Over the study period, the treatment satisfaction scale score increased in both groups from baseline to week 10, and continued to increase slightly thereafter in the target-achieved group and almost leveled off in the target-not-achieved group, similar to the change in HbA1c level (Fig. 3a) . Mean score of each item significantly improved from baseline to the final evaluation point (P\0.0001 for all) with significantly greater improvement in the target-achieved group (P\0.05 for all) (Fig. 3b) .
The mean DTSQs score of perceived frequency of hyperglycemia significantly improved from baseline to the final evaluation point in both groups (P\0.0001 for both) ( Fig. 3c) with significantly greater improvement in the target-achieved group (P = 0.0014). Mean score shift over time followed the same pattern as the treatment satisfaction scale score and the HbA1c level.
Mean hypoglycemia scores increased in both groups from baseline to the final evaluation point with small changes in actual values (1.2 to 1.4 and 1.0 to 1.4) without significant intergroup difference in the change (P = 0.6706) (Fig. 3c) .
The mean DTSQc treatment satisfaction scale score at the final evaluation point was 9.4 in overall patients. The score in the target- P\0.001 for all) (Fig. 3d,  e) . Mean hyperglycemia and hypoglycemia scores at the final evaluation point were significantly lower in the target-achieved than target-not-achieved group indicating a greater reduction in the perceived frequency of hyperglycemia and hypoglycemia in the target-achieved group (hyperglycemia: -0.9 and 0.0, respectively, P\0.0001; hypoglycemia: -0.7 and -0.4, respectively, P = 0.0041) (Fig. 3f ).
Of the data at baseline and final evaluation point analyzed to explore possible factors associated with treatment satisfaction by high, middle, and low satisfaction groups, the proportion of the patients with diabetic nephropathy and those with renal dysfunction were significantly smaller in the high satisfaction and larger in low satisfaction group (P\0.05 for all) ( Table 2 ). HbA1c and FPG levels were not significantly different at baseline between groups, although they were at the final evaluation point (highest in the low and lowest in the high satisfaction group, P\0.05 for all). More patients in the low satisfaction group (8.6%) than the others (middle and high satisfaction groups: 5.3 and 4.7%, respectively) reported hypoglycemic events as treatment-related adverse events, but without significant inter-group difference (P = 0.1613).
EQ-5D
Overall patients reported relatively good health status (i.e., 75.9-94.8% of patients responded ''No problem'' in each item). The mean index (Fig. 4a) . In all dimensions in both groups, except self-care in the target archived group, the proportion of patients who answered that they had no problem increased from baseline to the final evaluation point (Table 3) . Greatest mean change, about 10%, was observed in the anxiety/depression dimension in the targetachieved group among all the dimensions in the groups. At the final evaluation point, no patient in either the target-achieved or the target-not-achieved group answered that they had ''extreme problems'' in the anxiety/ depression dimension.
The mean EQ-VAS score significantly increased from baseline to the final evaluation point (61.19-69.46, P\0.0001) across all samples and also increased in both groups (from 58.65 to 73.51 and from 62.10 to 68.01 in the target-achieved and target-not-achieved group, respectively, P\0.0001 for both). Mean change in score was significantly greater in the target-achieved group (P\0.0001), starting from the lower score at baseline (Fig. 4b) .
DISCUSSION
In this sub-analysis using data from the ALOHA2 study, we explored treatment satisfaction and self-reported health status in patients with T2DM in whom the oral treatment failed and glargine BOT started. Improvement in treatment satisfaction was reflected in both DTSQs and DTSQc. Further significant improvement in EQ-5D index score (range -0.11 to 1.0) from a mean baseline score of more than 0.8, representing good health status, in both groups suggests that health further improved after starting glargine BOT even in the patients originally regarding themselves in a good health state. The results showed that treatment satisfaction and selfreported health status were not compromised but rather all improved following introduction of glargine BOT, representing the effectiveness of the treatment from patients' perspectives.
A possible reason for the improvement in treatment satisfaction and self-reported health status despite insulin introduction may be attributed to perceived low frequency of hypoglycemia in contrast to the often held negative impression of insulin [27, 28] . DTSQs hypoglycemia item score slightly deteriorated or did not change, although DTSQc equivalent did improve. This contradiction may be due in given the retrospective impression that the hypoglycemia frequency had decreased and so imply importance of achieving glycemic control. DTSQc's higher responsiveness to change [24, 29] may support this inference. In addition to the improvement in HbA1c level, patients' perceived low frequency of hypoglycemia may have defied the anxiety toward insulin therapy, perhaps leading to improved treatment satisfaction and perceived health status. Our current findings along with previous consistent study results [13, 14, 30] may underscore the effectiveness and safety of insulin glargine added to OADs from both clinical and patient perspectives.
The current analysis suggests associations of 
CONCLUSION
In the patients with T2DM whose OAD treatment failed to achieve adequate glycemic 
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